As the demand for COVID vaccines decreases worldwide, Moderna is planning to release a RSV vaccine, pending U.S. approval.
Moderna posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales ...
The drugmaker is optimistic about higher sales with new vaccines and a little help from AI in the coming years.
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Moderna stock has declined by 36.54% over the past year. The past month has seen some recovery in the stock price ... due to declining demand for its COVID-19 vaccines. However, the company ...
Moderna had plenty to announce starting with COVID-19, where the company trumpeted its next-gen, refrigerator-stable vaccine for the ... year-to-date high closing price of $115.44.
Do you have questions surrounding COVID-19, the vaccine and impacts on our communities? ABC13 is committed to finding answers and connecting you with resources. Man deliberately gets 217 Covid ...
Mar. 8, 2024 — COVID-19 ... the century-old vaccine reduced tumors and extended survival for mice with liver ... Feb. 20, 2024 — A study has shown that shortly after an increase in ...
A Victorian coroner is investigating whether a young woman's death from heart inflammation after receiving her third Covid-19 jab was caused by the Moderna vaccine. Moderna's lawyers appeared ...
Moderna (MRNA ... to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% year-over-year in 2023. Yahoo Finance Health Reporter Anjalee Khemlani recaps her interview with ...
WATCH: Nobel in medicine goes to scientists whose work on mRNA led to COVID vaccine Hungarian-American Katalin Karikó and American Drew Weissman were cited for contributing vaccine development ...